How it all started: Tau and protein phosphatase 2A

Journal of Alzheimer's Disease

Volumn 37, Issue 3, 2013, Pages 483-494

  Liu, Chang ^a   Götz, Jürgen ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alzheimer's disease; frontotemporal dementia; nucleus; protein phosphatase 2A; SFPQ; tau; transcription factor

Indexed keywords

ISOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN;

ALZHEIMER DISEASE; CELL FRACTIONATION; ENZYME ACTIVITY; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; HUMANS; NEURONS; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 84892757167     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130503     Document Type: Review

References (119)

1. Iqbal K, Tellez-Nagel I, Grundke-Iqbal I (1974) Protein abnormalities in Huntington's chorea. Brain Res 76, 178-184.
2. Iqbal K, Wisniewski HM, Grundke-Iqbal I, Korthals JK, Terry RD (1975) Chemical pathology of neurofib-rils Neurofibrillary tangles of Alzheimer's presenile-senile dementia. J Histochem Cytochem 23, 563-569.
3. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
4. Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, Grundke-Iqbal I (2010) Alzheimer's disease neurofibrillary degeneration: Pivotal and multifactorial. Biochem Soc Trans 38, 962-966.
5. Götz J, Schild A (2003) Transgenic and knockout models of PP2A. Methods Enzymol 366, 390-403.
6. Iqbal K, Grundke-Iqbal I (2006) Discoveries of tau, abnormally hyperphosphorylated tau and others of neu-rofibrillary degeneration: A personal historical perspective. J Alzheimers Dis 9, 219-242.
7. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72, 1858-1862.
8. Dehmelt L, Halpain S (2005) The MAP2/Tau family of microtubule-associated proteins. Genome Biol 6, 204.
9. Al-Bassam J, Ozer RS, Safer D, Halpain S, Milligan RA (2002) MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments. J Cell Biol 157, 1187-1196.
10. Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, Goedert M, Amos LA, Spillantini MG (2007) Interaction of tau protein with the dynactin complex. EMBO J 26, 4546-4554.
11. Brion JP, Passareiro H, Nunez J, Flament-Durand D (1985) Mise en évidence de la protéine Tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol (Bruxelles) 95, 229-235.
12. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83, 4044-4048.
13. Delacourte A, Defossez A (1986) Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 76, 173-186.
14. Nukina N, Ihara Y (1986) One of the antigenic determinants of paired helicalfilamentsisrelatedtotau protein. J Biochem 99, 1541-1544.
15. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
16. Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neu-rofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci USA 83, 4040-4043.
17. Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigeninthe brainsofAlzheimer patients. Science 232, 648-650.
18. Wischik CM, Crowther RA, Stewart M, Roth M (1985) Subunit structure of paired helical filaments in Alzheimer's disease. J Cell Biol 100, 1905-1912.
19. Pierre M, Nunez J (1983) Multisite phosphorylation of tau proteins from rat brain. Biochem Biophys Res Commun 115, 212-219.
20. Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259, 5301-5305.
21. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wis-niewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
22. Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phospho-rylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (Tokyo) 99, 1807-1810.
23. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM (1989) Accumulation of abnormally phos-phorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 477, 90-99.
24. Goto S, Yamamoto H, Fukunaga K, Iwasa T, Matsukado Y, Miyamoto E (1985) Dephosphorylation of microtubule-associated protein 2, tau factor, and tubulin by calcineurin. J Neurochem 45, 276-283.
25. Yamamoto H, Saitoh Y, Fukunaga K, Nishimura H, Miyamoto E (1988) Dephosphorylation of microtubule proteins by brain protein phosphatases 1 and 2A, and its effect on microtubule assembly. J Neurochem 50, 1614-1623.
26. Hoshi M, Nishida E, Miyata Y, Sakai H, Miyoshi T, Ogawara H, Akiyama T (1987) Protein kinase C phosphorylates tau and induces its functional alterations. FEBS Lett 217, 237-241.
27. Baudier J, Cole RD (1987) Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. J Biol Chem 262, 17577-17583.
28. Hoshi M, Nishida E, Sakai H (1989) Characterization of a mitogen-activated, Ca2+-sensitive microtubule-associated protein-2 kinase. Eur J Biochem 184, 477-486.
29. Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM (1991) Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res 539, 11-18.
30. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-927.
31. Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K (1994) Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and-2C and its implication in Alzheimer disease. FEBS Lett 341, 94-98.
32. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 275, 5535-5544.
33. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K (2000) Role of protein phosphatase-2A and-1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 485, 87-93.
34. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K (2001) Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Lett 490, 15-22.
35. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K (2003) Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163, 845-858.
36. Kins S, Kurosinski P, Nitsch RM, Götz J (2003) Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A in transgenic mice. Am J Pathol 163, 833-843.
37. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
38. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2, 783-787.
39. Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Glycosylation of microtubule-associated protein tau: An abnormal post-translational modification in Alzheimer's disease. Nat Med 2, 871-875.
40. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357, 299-309.
41. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J (2003) Beta-amyloid induces PHF-like tau filaments in tissue culture. J Biol Chem 278, 40162-40168.
42. Pennanen L, Götz J (2005) Different tau epitopes define Abeta (42)-mediated tau insolubility. Biochem Biophys Res Commun 337, 1097-1101.
43. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB (2007) Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 18, 5060-5068.
44. Janssens V, Longin S, Goris J (2008) PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail). Trends Biochem Sci 33, 113-121.
45. Schmidt K, Kins S, Schild A, Nitsch RM, Hemmings BA, Götz J (2002) Diversity, developmental regulation and dis-tribution of murine PR55/B subunits of protein phosphatase 2A. Eur J Neurosci 16, 2039-2048.
46. Martens E, Stevens S, Janssens J, Götz J, Goris J, van Hoof C (2004) Genomic organisation, chromosomal localisation, tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice. J Mol Biol 336, 971-986.
47. Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol 166, 1761-1771.
48. Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K (2010) The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J 24, 4420-4432.
49. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, Iqbal K (2011) Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2 (PP2A)/SET. FEBS Lett 585, 2653-2659.
50. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K (1999) Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 259, 471-475.
51. Loven MA, Muster N, Yates JR, Nardulli AM (2003) A novel estrogen receptor alpha-associated protein, template-activating factor Ibeta, inhibits acetylation and transactivation. Mol Endocrinol 17, 67-78.
52. Kutney SN, Hong R, Macfarlan T, Chakravarti D (2004) A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-Ibeta in integrating chromatin hypoacetylation and transcriptional repression. J Biol Chem 279, 30850-30855.
53. Kato K, Okuwaki M, Nagata K (2011) Role of Template Activating Factor-I as a chaperone in linker histone dynamics. J Cell Sci 124, 3254-3265.
54. Madeira A, Pommet JM, Prochiantz A, Allinquant B (2005) SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cyto-plasmic subdomain. FASEB J 19, 1905-1907.
55. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J (2003) Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucle-osome assembly protein SET is its inhibitor. Cell 112, 659-672.
56. Qu D, Li Q, Lim HY, Cheung NS, Li R, Wang JH, Qi RZ (2002) The protein SET binds the neuronal Cdk5 activator p35nck5a and modulates Cdk5/p35nck5a activity. J Biol Chem 277, 7324-7332.
57. Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H, Wang JZ, Wang X (2013) Ser9 phosphorylation causes cytoplasmic detention of I2 (PP2A)/SETinAlzheimer disease. Neurobiol Aging 34, 1748-1758.
58. Torrent L, Ferrer I (2012) PP2A and Alzheimer disease. Curr Alzheimer Res 9, 248-256.
59. Götz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, Goedert M (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14, 1304-1313.
60. Götz J, Probst A, Ehler E, Hemmings B, Kues W (1998) Delayed embryonic lethality in mice lacking protein phos-phatase 2A catalytic subunit Calpha. Proc Natl Acad Sci USA 95, 12370-12375.
61. Götz J, Probst A, Mistl C, Nitsch RM, Ehler E (2000) Distinct role of protein phosphatase 2A subunit calpha in the regulation of E-cadherin and beta-catenin during development. Mech Dev 93, 83-93.
62. Evans DR, Myles T, Hofsteenge J, Hemmings BA (1999) Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms. J Biol Chem 274, 24038-24046.
63. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Götz J (2001) Reduced PP2A activity induces hyper-phosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 276, 38193-38200.
64. Schild A, Ittner LM, Götz J (2006) Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochem Biophys Res Commun 343, 1171-1178.
65. Bryant JC, Westphal RS, Wadzinski BE (1999) Methylated C-terminal leucine residue of PP2A catalytic subunit is important for bindingofregulatory Balpha subunit. Biochem J 339 (Pt 2), 241-246.
66. Schild A, Isenmann S, Tanimoto N, Tonagel F, Seeliger MW, Ittner LM, Kretz A, Ogris E, Götz J (2006) Impaired development of the Harderian gland in mutant protein phos-phatase 2A transgenic mice. Mech Dev 123, 362-371.
67. Louis JV, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S, Zwaenepoel K, Pijnenborg R, Landrieu I, Lippens G, Ledermann B, Götz J, Van Leuven F, Goris J, Janssens V (2011) Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopa-thy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci USA 108, 6957-6962.
68. Hahn K, Miranda M, Francis VA, Vendrell J, Zorzano A, Teleman AA (2010) PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation. Cell Metab 11, 438-444.
69. Ruediger R, Ruiz J, Walter G (2011) Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol 31, 3832-3844.
70. Pennanen L, Wolfer DP, Nitsch RM, Götz J (2006) Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav 5, 369-379.
71. Deters N, Ittner LM, Götz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun 379, 400-405.
72. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
73. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Götz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci USA 107, 13888-13893.
74. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2013) Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 33 (Suppl 1), S123-S139.
75. Loomis PA, Howard TH, Castleberry RP, Binder LI (1990) Identification of nuclear tau isoforms in human neuroblas-toma cells. Proc Natl Acad Sci USA 87, 8422-8426.
76. Brady RM, Zinkowski RP, Binder LI (1995) Presence of tau in isolated nuclei from human brain. Neurobiol Aging 16, 479-486.
77. Cross DC, Munoz JP, Hernandez P, Maccioni RB (2000) Nuclear and cytoplasmic tau proteins from human nonneu-ronal cells share common structural and functional features with brain tau. J Cell Biochem 78, 305-317.
78. Hua Q, He RQ (2003) Tau could protect DNA double helix structure. Biochim Biophys Acta 1645, 205-211.
79. Wei Y, Qu MH, Wang XS, Chen L, Wang DL, Liu Y, Hua Q, He RQ (2008) Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxidation. PLoS One 3, e2600.
80. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Tala-hari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buee L, Galas MC (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286, 4566-4575.
81. Bretteville A, Marcouiller F, Julien C, El Khoury NB, Petry FR, Poitras I, Mouginot D, Levesque G, Hebert SS, Planel E (2012) Hypothermia-induced hyperphosphorylation: A new model to study tau kinase inhibitors. Sci Rep 2, 480.
82. Ke Y, Dramiga J, Schutz U, Kril JJ, Ittner LM, Schroder H, Götz J (2012) Tau-Mediated Nuclear Depletion and Cyto-plasmic Accumulation of SFPQ in Alzheimer's and Pick's Disease. PLoS One 7, e35678.
83. Chu CT, Plowey ED, Wang Y, Patel V, Jordan-Sciutto KL (2007) Location, location, location: Altered transcription factor trafficking in neurodegeneration. J Neuropathol Exp Neurol 66, 873-883.
84. Yamada T, Yoshiyama Y, Kawaguchi N (1997) Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Res 749, 329-334.
85. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66, 75-85.
86. Chalovich EM, Zhu JH, Caltagarone J, Bowser R, Chu CT (2006) Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem 281, 17870-17881.
87. Neumann M, Sampathu DM, Kwong LK, Truax AC, Mic-senyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotem-poral lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
88. Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis 17, 531-539.
89. Gustke N, Trinczek B, Biernat J, Mandelkow EM, Man-delkow E (1994) Domains of tau protein and interactions with microtubules. Biochemistry (Mosc) 33, 9511-9522.
90. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA (1986) Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 387, 271-280.
91. Andreadis A (2012) Tau splicing and the intricacies of dementia. J Cell Physiol 227, 1220-1225.
92. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8, 711-715.
93. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF (2012) The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 124, 693-704.
94. Trabzuni D, Wray S, Vandrovcova J, Ramasamy A, Walker R, Smith C, Luk C, Gibbs JR, Dillman A, Hernandez DG, Arepalli S, Singleton AB, Cookson MR, Pittman AM, de Silva R, Weale ME, Hardy J, Ryten M (2012) MAPT expression and splicing is differentially regulated by brain region: Relation to genotype and implication for tauopathies. Hum Mol Genet 21, 4094-4103.
95. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85, 4051-4055.
96. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
97. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J 8, 393-399.
98. Goedert M, Jakes R, Crowther RA, Six J, Lubke U, Van-dermeeren M, Cras P, Trojanowski JQ, Lee VM (1993) The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci USA 90, 5066-5070.
99. Brion JP, Smith C, Couck AM, Gallo JM, Anderton BH (1993) Developmental changesintau phosphorylation: Fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. J Neurochem 61, 2071-2080.
100. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Tro-janowski JQ, Lee VM (1998) Mutation-specific functional impairmentsin distinct tau isoforms of hereditary FTDP-17. Science 282, 1914-1917.
101. McMillan P, Korvatska E, Poorkaj P, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I (2008) Tau isoform regulation is region-and cell-specific in mouse brain. J Comp Neurol 511, 788-803.
102. Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S, Matsui T, Growdon JH, Frosch MP, Ghetti B, Brown RH, Irizarry MC, Hyman BT (2007) Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 114, 471-479.
103. Lee G, Neve RL, Kosik KS (1989) The microtubule binding domain of tau protein. Neuron 2, 1615-1624.
104. Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L (2003) Differential regulation of microtubule dynamics by three-and four-repeat tau: Implications for the onset of neurodegenerative disease. Proc Natl Acad Sci USA 100, 9548-9553.
105. Goode BL, Feinstein SC (1994) Identification of a novel microtubule binding and assembly domain in the develop-mentally regulated inter-repeat region of tau. J Cell Biol 124, 769-782.
106. Goode BL, Chau M, Denis PE, Feinstein SC (2000) Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onsetofneurodegenetative disease. J Biol Chem275, 38182-38189.
107. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Man-delkow EM, Mandelkow E (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276, 48165-48174.
108. Zhong Q, Congdon EE, Nagaraja HN, Kuret J (2012) Tau isoform composition influences rate and extent of filament formation. J Biol Chem 287, 20711-20719.
109. Bhaskar K, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem 280, 35119-35125.
110. Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 131, 1327-1340.
111. Maas T, Eidenmuller J, Brandt R (2000) Interaction of tau with the neural membrane cortex is regulated by phospho-rylation at sites that are modified in paired helical filaments. J Biol Chem 275, 15733-15740.
112. Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G (1998) Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci 111, 3167-3177.
113. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H (2004) Phosphorylation of tau by fyn: Implications for Alzheimer's disease. J Neurosci 24, 2304-2312.
114. Belkadi A, LoPresti P (2008) Truncated tau with the Fyn-binding domain and without the microtubule-binding domain hinders the myelinating capacity of an oligodendro-cyte cell line. J Neurochem 107, 351-360.
115. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11, 909-913.
116. Karch CM, Jeng AT, Goate AM (2012) Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem 287, 42751-42762.
117. Ittner LM, Götz J (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
118. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet377, 1019-1031.
119. Götz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 165, 1246-1259.